
-
Miami struggle to 2-0 win over Jamaica's Cavalier
-
China will 'firmly counter' US trade pressure: top diplomat
-
Playmaker O'Connor to put sentiment aside when Crusaders meet Reds
-
'Eerie' sky, charred bodies: 80 years since Tokyo WWII firestorm
-
Once a crumbling relic of old Iran, brewery reborn as arts hub
-
Djokovic seeks Indian Wells resurgence with help from Murray
-
Musk's SpaceX faces new Starship setback
-
Trump signs executive order establishing 'Strategic Bitcoin Reserve'
-
Australian casino firm scrambles for cash to survive
-
NYC High Line architect Scofidio dead at 89
-
Musk's SpaceX faces setback with new Starship upper stage loss
-
Australians told 'prepare for worst' as tropical cyclone nears
-
Clark edges two clear at Arnold Palmer Invitational
-
Super cool: ATP sensation Fonseca learning to deal with demands of fame
-
Trump again casts doubt on his commitment to NATO
-
EU leaders agree defence boost as US announces new talks with Kyiv
-
48 killed in 'most violent' Syria unrest since Assad ouster: monitor
-
US and European stocks gyrate on tariffs and growth
-
Deja vu on the Moon: Private US spaceship again lands awkwardly
-
Brazilian teen Fonseca into Indian Wells second round
-
Abortion access under threat in Milei's Argentina
-
Trump backs off Mexico, Canada tariffs after market blowback
-
Trump car tariff pivot and Detroit's 'Big Three'
-
Man Utd draw in Spain in Europa League last 16 as Spurs beaten
-
California's Democratic governor says trans women in sports 'unfair'
-
Trump says Musk should use 'scalpel' not 'hatchet' in govt cuts
-
Goodall, Shatner to receive environmentalist awards from Sierra Club
-
Dingwall glad to be 'the glue' of England's back-line against Italy
-
Chelsea edge Copenhagen in Conference League last 16 first leg
-
Real Sociedad fight back to earn Man United draw in Europa League
-
Chunky canines: Study reveals dog obesity gene shared by humans
-
Europe rallies behind Zelensky as US announces new talks with Kyiv
-
Drop in US border crossings goes deeper than Trump
-
Guyana appeals to UN court as Venezuelan plans vote in disputed zone
-
Private US spaceship lands near Moon's south pole in uncertain condition
-
Saudi PIF to pay 'up to 12 months maternity leave' for tennis players
-
16 killed in 'most violent' Syria unrest since Assad ouster: monitor
-
Peru farmer confident ahead of German court battle with energy giant
-
US-Hamas talks complicate Gaza truce efforts: analysts
-
European rocket successfully carries out first commercial mission
-
SpaceX gears up for Starship launch as Musk controversy swirls
-
Trump backs off Mexico tariffs while Canada tensions simmer
-
Europe's new rocket blasts off on first commercial mission
-
SpaceX gearing up for Starship launch amid Musk controversy
-
Racked by violence, Haiti faces 'humanitarian catastrophe': MSF
-
Gisele Pelicot's daughter says has filed sex abuse case against father
-
New Zealand set for 'scrap' with India on slower pitch: Santner
-
US signals broader tariff reprieve for Canada, Mexico as trade gap grows
-
US to carry out first firing squad execution since 2010
-
Roy Ayers, godfather of neo-soul, dead at 84

From Covid to cancer: High hopes for Nobel mRNA vaccines
The coronavirus pandemic brought global renown to the mRNA technology that underpins vaccines from Pfizer/BioNTech and Moderna, and on Monday earned a Nobel Prize for two scientists who have been key to its development.
Katalin Kariko of Hungary and Drew Weissman of the United States won the Nobel Medicine Prize for their work on "nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".
These types of jabs are new but researchers have been working for decades to try to figure out how to use messenger RNA (ribonucleic acid) for other vaccinations and to treat illnesses from AIDS to cancer.
- How does it work? -
Messenger RNA's job in the body is to help deliver specific instructions from DNA to cells.
In the case of the Pfizer/BioNTech and Moderna jabs, lab-generated mRNA tells human cells to create antigens -- proteins that are similar to ones found in the Covid-19 virus.
Thanks to those antigens, a person's immune system learns how to fight the virus and neutralise Covid if it enters the body.
After the cells create these proteins, the body breaks down the mRNA instructions and gets rid of them.
Such direct communication with cells is revolutionary -- classic vaccines aimed to provoke an immune response by injecting a neutralised form of a virus or antigens into the system.
- Where did this come from? -
The first big breakthrough, in the late 1970s, was in using mRNA to make test-tube cells produce proteins.
A decade later, scientists were able to get the same results in mice, but mRNA still had two major drawbacks as a medical tool.
For one thing, cells in live animals resisted synthetic mRNA, provoking a dangerous immune response.
On top of that, mRNA molecules are fragile, making them difficult to deliver to the system without altering them.
In 2005, Kariko and Weissman of Penn State University published a groundbreaking study showing that a lipid -- or fat molecule -- envelope could safely deliver mRNA without negative effects.
The research caused a buzz in the pharmaceutical community and start-ups dedicated to mRNA therapies began to pop up around the world.
- What else can mRNA do? -
Scientists have worked on developing mRNA jabs for illnesses like seasonal flu, rabies and Zika, as well as those that have remained vaccine-resistant until now, including malaria and AIDS.
Researchers have also started testing personalised treatments on cancer patients, using samples of the proteins in their tumours to create specialised mRNA.
This then triggers the immune system to target specific cancer cells.
"The mRNA platform is versatile," University of Pennsylvania biochemist Norbert Pardi told AFP. "Any protein can be encoded as mRNA so there are many potential applications."
G.Stevens--AMWN